araag2/HINT huggingface dataset:
Clinical trial NCT02870205 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis (sar)
ICD codes: J30.2
Drugs: gsp 301 ns, gom-ns, gmm-2 ns, gsp 301 placebo ns
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and non-pregnant females who are 12 years of age and older.

          -  Documented clinical history of SAR (for at least 2 years preceding the Screening Visit
             [Visit 1]) with exacerbations (clinical evidence of active symptoms) for the relevant
             seasonal allergen during the Fall or mountain cedar allergy seasons (e.g., ragweed or
             mountain cedar pollen)

          -  A 12-hour rTNSS ≥8 out of a possible 12 and a congestion score ≥2 for the AM
             assessment at the Screening Visit (Visit 1).

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  History of anaphylaxis and/or other severe local reaction(s) to skin testing.

          -  History of positive test for HIV, Hepatitis B or Hepatitis C infection.

          -  Documented evidence of acute or significant chronic sinusitis or chronic purulent
             postnasal drip.

          -  Subjects with an active pulmonary disorder or infection.

          -  Subjects with posterior subcapsular cataracts or glaucoma

          -  Plans to travel outside the known pollen area for the investigational site for 24
             hours or longer during the last 7 days of the run-in period.
Clinical trial NCT02870790 (phase 3, status: completed)
Conditions: hiv, sti
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: tdf/ftc
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  HIV negative at enrolment, with a negative HIV test result documented within seven
             days of initiating PrEP

          -  At high and ongoing risk for acquiring HIV infection through sexual exposure (as
             defined by Behavioural Eligibility criteria presented in Appendix II and online Risk
             Assessment Questionnaire in Appendix III), OR previously a PrELUDE study participant

          -  Aged 18 years or over

          -  Live in NSW or ACT or visit NSW or ACT enough to attend clinics for follow-up
             assessments

          -  Willing and able to provide informed consent

          -  Medicare ineligible individuals may be enrolled if the clinical service is able to
             cover the costs of monitoring of the patient

        Exclusion Criteria:

          -  HIV-1 infected or has symptoms consistent with acute viral infection (If HIV positive
             status is not confirmed by testing, delay starting PrEP for at least one month and
             reconfirm negative HIV-1 status).

          -  Having an estimated creatinine clearance (glomerular filtration rate [GFR]) <60ml/min

          -  Having or developing clinical symptoms suggestive of lactic acidosis or pronounced
             hepatotoxicity (including nausea, vomiting, unusual or unexpected stomach discomfort,
             and weakness)

          -  Concurrently taking a nephrotoxic agent (e.g., high-dose non-steroidal
             anti-inflammatory drugs / NSAIDs)

          -  Allergic to TDF and/or FTC (based on self-report or recorded)

          -  Concurrently taking prescribed products containing FTC or TDF including ATRIPLA®,
             COMPLERA®, EMTRIVA, STRIBILD®, VIREAD, TAF (tenofovir alafenamide), GENVOYA, DESCOVY;
             other drugs containing lamivudine; HEPSERA

          -  Factors or conditions that may compromise a participant's access to health services
             for follow-up (incarceration or planned relocation and potential absence from NSW or
             ACT).

        Behavioural eligibility criteria as per NSW PrEP guidelines.
Clinical trial NCT02873221 (phase 3, status: completed)
Conditions: migraine, with or without aura
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: ubrogepant, placebo-matching ubrogepant, usual care
SMILES: CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

        -Completed study UBR-MD-01(NCT02828020) or UBR-MD-02(NCT02867709).

        Exclusion Criteria:

          -  Patients with clinically significant electrocardiogram (ECG), vital sign, physical
             exam, or laboratory abnormalities

          -  Requirement for a medication during the study that is on the list of prohibited
             medications.
Clinical trial NCT02873936 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: filgotinib, placebo to match filgotinib, csdmards
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Have a diagnosis of RA (2010 American College of Rheumatology [ACR]/European League
             Against Rheumatism [EULAR] criteria for RA), and are ACR functional class I-III.

          -  Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints [SJC66]) and ≥6
             tender joints (from a tender joint count based on 68 joints [TJC68]) at screening and
             Day 1

          -  Ongoing treatment with a stable prescription of 1 or 2 csDMARDs

          -  Have received at least one biologic disease modifying antirheumatic drug (bDMARD) for
             the treatment of RA to which they have had an inadequate response or intolerance

        Key Exclusion Criteria:

          -  Previous treatment with any janus kinase (JAK) inhibitor

        NOTE: Other protocol Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02875834 (phase 3, status: completed)
Conditions: hyperkalemia
ICD codes: E87.5, P74.31
Drugs: sodium zirconium cyclosilicate (zs) 10g, sodium zirconium cyclosilicate (zs) 5g, sodium zirconium cyclosilicate (zs) 10g, placebo
SMILES: O.O.[Na+].[Na+].O[Si](O)(O)O.O[Si](O)(O)O.O[Si](O)(O)O.O[Zr](O)(O)(O)([O-])[O-], O.O.[Na+].[Na+].O[Si](O)(O)O.O[Si](O)(O)O.O[Si](O)(O)O.O[Zr](O)(O)(O)([O-])[O-], O.O.[Na+].[Na+].O[Si](O)(O)O.O[Si](O)(O)O.O[Si](O)(O)O.O[Zr](O)(O)(O)([O-])[O-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Female and male patients aged ≥18 and ≤ 90 years

          -  Two consecutive i-STAT potassium values, measured 60-minutes (± 10 minutes) apart,
             both ≥ 5.1 mmol/l and measured within 1 day of the first ZS dose on 48-hour open-label
             initial phase Day 1

          -  Ability to have repeated blood draws or effective venous catheterization

          -  Female patients must be 1 year post-menopausal, surgically sterile, or using an
             acceptable method of contraception for the duration of the study and for 3 months
             after the last dose of ZS/matching placebo to prevent pregnancy.

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study

          -  Participation in another clinical study with an investigational product during the
             last 3 months

          -  Pseudohyperkalemia signs and symptoms

          -  Patients treated with lactulose, xifaxan (rifaximin) or other non-absorbed antibiotics
             for hyperammonemia within 7 days prior to the first dose of study drug

          -  Patients treated with resins,calcium acetate,calcium carbonate, or lanthanum
             carbonate,within 7 days prior to the first dose of study drug

          -  Patients with a life expectancy of less than 3 months

          -  Patients who are severely physically or mentally incapacitated and who in the opinion
             of investigator are unable to perform the subjects' tasks associated with the protocol

          -  Female patients who are pregnant, lactating, or planning to become pregnant

          -  Patients with diabetic ketoacidosis

          -  Presence of any condition which, in the opinion of the investigator, places the
             patient at undue risk or potentially jeopardizes the quality of the data to be
             generated

          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof

          -  Patients with cardiac arrhythmias that require immediate treatment

          -  Patients on dialysis

          -  Patients who are blood donors should not donate blood during the study and for 3
             months following their last dose of ZS
Clinical trial NCT02876900 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: low dose asenapine maleate transdermal patch, high dose asenapine maleate transdermal patch, placebo
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Current diagnosis of schizophrenia.

          -  Subject has PANSS total score ≥80, AND score of 4 or more in at least 2 of the
             following PANSS items at Screening and at Baseline: conceptual disorganization
             delusions; hallucinatory behavior; unusual thought content.

          -  Subjects must be able to wear a transdermal patch for 24 hours.

        Exclusion Criteria:

          -  Subject has been diagnosed with schizophrenia less than 6 months prior to Screening
             Visit.

          -  Subject has received within 90 days of Screening Visit: electroconvulsive therapy;
             transcranial magnetic stimulation; vagal nerve stimulation; or other brain stimulation
             treatments

          -  Subject has experienced acute depressive symptoms within 30 days prior to Screening
             Visit that requires treatment with an antidepressant, as determined by the
             Investigator.

          -  Currently taking clozapine for the treatment of schizophrenia.

          -  Has hypothyroidism or hyperthyroidism.

          -  Subject is currently being treated with insulin for diabetes.

          -  Subject has epilepsy or history of seizures.

          -  Positive urine pregnancy test.
Clinical trial NCT02877927 (phase 3, status: completed)
Conditions: bacterial infections, skin structures and soft tissue infections
ICD codes: A49.9, A04.9, A04.8, A49.8
Drugs: omadacycline, linezolid
SMILES: [H][C@@]12CC3=C(C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C, CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients, ages 18 years or older who have signed the informed consent

          -  Has a qualifying skin and skin structure infection

          -  Female patients must not be pregnant at the time of enrollment

          -  Must agree to a reliable method of birth control during the study and for 30 days
             following the last dose of study drug

        Exclusion Criteria:

          -  Infections where the outcome is strongly influenced by factors other than
             protocol-defined treatments and procedures, or that require antibacterial treatment
             for greater than 14 days

          -  Evidence of significant immunological disease

          -  Severe renal disease or requirement for dialysis

          -  Evidence of septic shock

          -  Has a history of hypersensitivity or allergic reaction to any tetracycline or to
             linezolid

          -  Has received an investigational drug within the past 30 days

          -  Women who are pregnant or nursing
Clinical trial NCT02885636 (phase 3, status: completed)
Conditions: congestive heart failure, heart failure, left-sided, left-sided heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40, K51.50, K51.513, K51.514, K51.511, K51.512, K51.518, K51.519, K51.50, K51.513, K51.514, K51.511, K51.512, K51.518, K51.519
Drugs: albuterol
SMILES: CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Heart Failure with Preserved Ejection Fraction (HFpEF)

          -  Normal left ventricular ejection fraction (≥50%)

          -  Elevated Left Ventricular filling pressures at cardiac catheterization (defined as
             resting Pulmonary Capillary Wedge Pressure>15 mmHg and/or ≥25 mmHg during exercise).

        Exclusion Criteria:

          -  Prior albuterol therapy (within previous 48 hours)

          -  Current long acting inhaled beta agonist use

          -  Significant hypokalemia (<3meq/L)

          -  Significant valvular disease (>moderate left-sided regurgitation, >mild stenosis)

          -  High output heart failure

          -  Severe pulmonary disease

          -  Unstable coronary disease

          -  Constrictive pericarditis

          -  Restrictive cardiomyopathy

          -  Hypertrophic cardiomyopathy
Clinical trial NCT02886702 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: tazarotene cream 0.05%, tazorac® (tazarotene) cream 0.05%, placebo
SMILES: CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1, CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a definite clinical diagnosis of stable (at least 6 months) plaque psoriasis,
             involving at least 2% and no more than 20% of the body surface area (BSA) (not
             including the scalp and intertriginous areas)

          -  Have a minimum plaque elevation at the target lesion site of at least moderate
             severity (grade ≥ 3 on the Psoriasis Area Severity Index [PASI]). The most severe
             lesion at baseline should be identified as the target lesion

          -  Have an Investigator's Global Assessment (IGA) of disease severity of at least
             moderate (score ≥ 3) as an overall assessment of all lesions to be treated.

        Exclusion Criteria:

          -  A female subject who is pregnant, nursing, planning a pregnancy, or does not agree to
             use an acceptable form of birth control within the study participation period

          -  Have a current diagnosis of unstable forms of psoriasis in the treatment area,
             including pustular, guttate, exfoliative or erythrodermic psoriasis

          -  Have a history of psoriasis unresponsive to topical treatments
Clinical trial NCT02886728 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: filgotinib, placebo to match filgotinib, mtx, placebo to match mtx
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Have a diagnosis of RA (2010 American College of Rheumatology [ACR]/European League
             Against Rheumatism [EULAR] criteria) and are ACR functional class I-III.

          -  Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥
             6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both
             screening and Day 1.

          -  Limited or no prior treatment with MTX

        Key Exclusion Criteria:

          -  Previous treatment with any janus kinase (JAK) inhibitor

          -  Previous therapy for longer than 3 months with conventional synthetic disease
             modifying antirheumatic drugs (csDMARDs) other than MTX or hydroxychloroquine

          -  Use of any licensed or investigational biologic disease-modifying antirheumatic drugs
             (DMARDs)

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02888444 (phase 3, status: terminated)
Conditions: chronic obstructive pulmonary disease, smoking cessation
ICD codes: J44.9, J44.1, J44.0, Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: varenicline, placebo
SMILES: [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    poor recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Daily smokers

          -  Diagnosed with COPD (as per the Global Initiative for Chronic Obstructive Lung Disease
             [GOLD] criteria, namely: a characteristic clinical picture of dyspnea, cough or
             sputum, with a history of exposure to risk factors, plus a post-bronchodilator forced
             expiratory volume in one second / forced vital capacity FEV1/FVC ratio of <0.70)

          -  Have stable COPD (i.e. no exacerbation, hospital admission, or use of antibiotics or
             prednisone in the past six weeks)

          -  Can provide consent

          -  Reside in the Auckland region of New Zealand

          -  Eligible under New Zealand special authority to receive subsidised varenicline

          -  Prepared to make a quit attempt with varenicline

          -  Have access to a phone

        Exclusion Criteria:

          -  A history of definite asthma and/or atopy

          -  Contraindications to varenicline

          -  Used varenicline in the past 12 months

          -  A history of serious psychiatric illness or significant cognitive impairment

          -  Major or uncontrolled co-morbidities (such as uncontrolled heart failure, infection or
             rapidly progressive condition)

          -  A life expectancy of < 12 months

          -  Are currently using another cessation medication (including e-cigarettes)
Clinical trial NCT02889796 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: filgotinib, placebo to match filgotinib, adalimumab, placebo to match adalimumab, mtx
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Have a diagnosis of rheumatoid arthritis (RA) [2010 American College of Rheumatology
             (ACR)/European League Against Rheumatism (EULAR) criteria] , and are ACR functional
             class I-III.

          -  Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥
             6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both
             screening and Day 1.

          -  Ongoing treatment with a stable dose of MTX

        Key Exclusion Criteria:

          -  Previous treatment with any janus kinase (JAK) inhibitor

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02890173 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: cs-3150, eplerenone
SMILES: [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects aged 20 years or older at informed consent

          -  Subjects with essential hypertension satisfying the following blood pressure criteria;

               -  Sitting SBP: ≥ 140 mmHg and < 180 mmHg

               -  Sitting DBP: ≥ 90 mmHg and < 110 mmHg

               -  Mean 24 hr BP: SBP ≥ 130 and DBP ≥ 80 mmHg

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  Diabetic nephropathy or diabetes mellitus with albuminuria

          -  Serum potassium level < 3.5 or ≥ 5.1 mEq/L

          -  Reversed day-night life cycle including overnight workers

          -  eGFR < 60 mL/min/1.73 m^2
Clinical trial NCT02896127 (phase 3, status: completed)
Conditions: ankylosing spondyloarthritis
ICD codes: M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7, M45.A0
Drugs: secukinumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Male or non-pregnant, non-lactating female patients at least 18 years of age

        Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray or
        radiologist's report) fulfilling the Modified New York criteria for AS:

          -  Active AS assessed by BASDAI ≥4 (0-10) at Baseline

          -  Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at Baseline

          -  Total back pain as measured by VAS ≥ 40 mm (0-100 mm) at Baseline Patients should have
             had inadequate response or failure to respond to at least 2 NSAIDs at an approved dose
             for a minimum of 4 weeks in total and a minimum of 2 weeks for each NSAID prior to
             randomization, or less than 4 weeks if therapy had to be withdrawn due to intolerance,
             toxicity or contraindications Patients who are regularly taking NSAIDs (including
             COX-1 or COX-2 inhibitors) as part of their AS therapy are required to be on a stable
             dose for at least 2 weeks before randomisation Patients who have been on a TNFα
             inhibitor (not more than one) must have experienced an inadequate response to previous
             or current treatment given at an approved dose for at least 3 months prior to
             randomization or have been intolerant to at least one administration of an anti-TNFα
             agent

        Exclusion Criteria:

          -  Chest X-ray or MRI with evidence of ongoing infectious or malignant process

               -  Patients taking high potency opioid analgesics

               -  Previous exposure to secukinumab or any other biologic drug directly targeting
                  IL-17 or IL-17 receptor

               -  Pregnant or nursing (lactating) women
Clinical trial NCT02896205 (phase 3, status: completed)
Conditions: systemic sclerosis, scleroderma, interstitial lung disease
ICD codes: M34.0, M34.89, M34.9, M34.82, M34.83, M34.81, M34.2, L94.1, L94.0, J84.115, J84.170, J84.848
Drugs: mycophenolate mofetil, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients of systemic sclerosis with presence of interstitial lung disease on High
             Resolution Computer Tomography (HRCT) chest

          2. FVC ≥ 70% of predicted on pulmonary function tests

          3. Age ≥18 years

          4. Consenting for participating in study

        Exclusion Criteria:

          1. Received immunosuppression (except low dose steroids, prednisolone equivalent ≤10
             mg/day) for ILD in the last 3 years

          2. Persistent leucopenia or thrombocytopenia

          3. Pregnant or breastfeeding females

          4. Severe pulmonary arterial hypertension (mean pulmonary arterial pressure >55mmHg)
             requiring drug therapy

          5. Uncontrolled congestive heart failure

          6. Any other abnormalities noted on chest X-ray or HRCT other than ILD

          7. Active infection

          8. Inflammatory myositis

          9. Overlap syndrome

         10. Mixed connective tissue disease

         11. Other serious co-morbidities which could compromise patient's ability to complete the
             study